Abstract Library

#2896 Comparative Genomic Analysis of High Grade Neuroendocrine Neoplasms across Diverse Organs

Introduction: Grade 3 neuroendocrine neoplasms (G3 NENs), if poorly differentiated, have a median survival of 10-19 months. Little is known regarding biologic differences between G3 NENs from different primary sites, most commonly GI and lung.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Sun T

Authors: Sun T, Van Hummelen P, Martin B, Xia C, Zhao L,

Keywords: grade 3, high grade, neuroendocrine carcinoma, whole exome sequencing, rna-seq, transcriptomics, copy number analysis, sequencing, genomics, poorly differentiated,

#2175 A Retrospective Analysis of 344 Cases with Neuroendocrine Neoplasms

Introduction: Ki-67 is a nuclear protein that is strictly associated with cellular proliferation，acting as a cellular marker for proliferation in clinical practice to determine the degree to which the tumor cells are duplicating. Ki-67 index strongly ties to the prognosis and provides guiding significance to clinical decisions.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Liu Z, Zhao H, Wu Y, Jiang L, Shi S,

Keywords: ki-67 index, neuroendocrine neoplasm, prognosis,

#2174 Clinicopathologic Features and Treatment Outcome of 225 Newly Diagnosed Pulmonary Carcinoids: A Single Center Experience of 28 Years

Introduction: Data on pulmonary carcinoids are scarce.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Li Q

Authors: Li Q, Zhou Y, Zhang Y, Chi Y, Zhao H,

Keywords: pulmonary carcinoids, surgery, Chinese,

#2131 Clinical Analysis of 15 Cases of Gallbladder Neuroendocrine Carcinoma

Introduction: Primary gallbladder neuroendocrine carcinoma is a relatively rare disease.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Zhang Y

Authors: Zhang Y, Chen X, Wang Y, Zhao J, Li Z,

Keywords: gallbladder neuroendocrine carcinoma, clinicopathological features, prognosis,

#1743 FOLFIRI Regimen with or without Bevacizumab As Second-Line Therapy Showed Activity in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Carcinoma

Introduction: Metastatic disease of GEP-NEC is tough condition in clinical practice. And the role of the second-line therapy remains unknown

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: ZHIYU C

Authors: Chen Z, Zhao X, Wang C, Zhang W, Zhu X,

Keywords: NEC, FOLFIRI, bevacizumab ,